Carboplatin/olaparib plus AVB-500, a selective inhibitor of GAS6-AXL, can increase DNA damage and RAD51 focus formation and slow replication fork progression, resulting in rapid death of ovarian cancer cells in vitro and decreased tumor burden in vivo [131]. The gene discussed is AXL; the disease is neoplasm.